.@sjainind, Secretary General, IPA, on @CNBCTV18Live: the 30% trade margin cap on 137 anti-cancer medicines, effective 9 Nov, is expected to lower prices on 1,000+ brands at the point of purchase. The cap applies to the distribution chain, not to manufacturers. India supplies some of the lowest-cost medicines in the world; a holistic view of access, supply and investment keeps it that way. #IndianPharma @Pharmadept

Affordable, quality-assured cancer care depends on every link in the supply chain working together. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance, shares IPA’s perspective on the Government’s trade margin rationalisation for cancer medicines. He calls it a balanced step that puts patient welfare first. India’s pharmaceutical industry remains committed to making quality medicines accessible to every patient who needs them. @sjainind @Pharmadept #IPA #IndianPharma #CancerCare #PatientAccess #AffordableMedicines

The New York Times went inside India’s pharmaceutical industry to understand why the world’s largest medicine market still depends on it for generics. The answer runs deeper than cost. Five things the piece makes clear: The scale is hard to replace Generics fill 90% of US prescriptions. 40% of those generics are made in India. Few industries anywhere carry that share of another country’s daily medicine supply. The capability was built over fifty years India entered generics in the 1970s. By the time its patent law aligned with WTO standards in 2005, its manufacturers were already supplying Asia, Africa and Latin America. @sjainind , Secretary General, Indian Pharmaceutical Alliance, to the NYT: “In the U.S., once it goes out of patent, you forget about it. But in India, the entrepreneurs keep on working and developing it, and at these volumes, you get better at making it.” The quality bar has moved with the volumes US FDA inspections of Indian plants are now unannounced, and the industry’s large manufacturers are clearing them. The standard India’s generics are built to today is the one the world’s most demanding regulator applies. The pipeline is widening Over the next five to seven years, 55 major patents worth about USD 300 billion a year will expire in the US. Each one is a medicine Indian manufacturers can make more affordable. The future is interdependent Medicine supply chains do not split neatly by country. Much of the world’s active ingredient supply, India’s included, comes from a single source. Mr Jain told the NYT this creates an opportunity for India and the US to build their pharmaceutical capabilities together rather than pull them apart. Read the full article (subscription may be required): nytimes.com/2026/10/02/busin… #IndianPharma #Generics #GlobalHealth #PharmaSupplyChain

A spurious drug is not a brand problem. It is a patient safety problem. Session 6 of the 11th Advanced GMP Workshop opened Day 2 with anti-counterfeit and supply chain integrity. Ranga Chandrasekhar, Joint Drugs Controller (India), CDSCO, set out what government, regulators and industry each bring to the fight against spurious medicines: stronger penalties, the phased rollout of QR codes and track-and-trace, and the gaps that remain between the manufacturer and the retail shelf. Dr. Keshav Kumar, Senior Advisor, IPA, brought a law enforcement lens: counterfeiting is organised crime, and investigation has to follow the money and the network, not just the seized product. The message from both: eradicating spurious drugs needs every link in the chain working on the same system, and every stakeholder treating it as their problem. Day 2 is live now. Watch here: youtube.com/live/jHDpJgyp0XY #AdvancedGMP #SupplyChainIntegrity #AntiCounterfeit #PatientSafety #IndianPharma

Day 1 of the 11th Advanced GMP Workshop set the baseline: where Indian pharma stands on quality today, and where the next decade needs to take it. Day 2 moves from quality systems to how quality is built and secured. The morning opened with Session 6 on anti-counterfeit and supply chain integrity, with Ranga Chandrasekhar, Joint Drugs Controller (India), CDSCO, and Dr. Keshav Kumar, Senior Advisor, IPA. Ahead: backward integration of APIs, quality leadership, sterility assurance, and a look back at the history of manufacturing practices in India. Watch Day 2 live: youtube.com/live/jHDpJgyp0XY #AdvancedGMP #GMP #PharmaQuality #SupplyChainIntegrity #IndianPharma

Same observations, different inspections. Why? Session 2 of the 11th Advanced GMP Workshop brought a regulator's view and an industry view together: Rafeeq Habeeb of the US FDA India Office on recurring observation trends, and Shirish Ambulgekar, Global Quality Head at Alkem, on what they say about quality culture. Day 2 is tomorrow from 3 PM IST. Register now: online-sound.zoom.us/webinar… #AdvancedGMP #GMP #PharmaQuality #QualityCulture #IndianPharma

The 11th Advanced GMP Workshop opened today with a clear message from regulators and industry leaders: India's position in the global medicine supply chain brings opportunity and responsibility in equal measure. From the inaugural session, four voices on what the next decade of GMP quality systems will ask of the Indian pharmaceutical industry. Swipe through. Day 2 continues tomorrow from 3 PM IST. Registration now: online-sound.zoom.us/webinar… #AdvancedGMP #GMP #PharmaQuality #IndianPharma

The 11th Advanced GMP Workshop begins today. Over two days, global regulators and industry leaders will discuss GMP quality systems and what comes next. Day 1 starts at 3:00 PM IST, online. Join us: online-sound.zoom.us/webinar…

1 day to go. The 11th Advanced GMP Workshop opens tomorrow, 8 October, 3:00 PM IST. Regulators from the US FDA, CDSCO, MHRA and PMDA join industry quality leaders. Online and free. Register now: online-sound.zoom.us/webinar… #AdvancedGMP

2 days to go. Day 2 of IPA's 11th Advanced GMP Workshop brings CDSCO, EDQM and industry quality leaders together on supply chain integrity, APIs and CDMOs, quality leadership, sterility assurance and the history of manufacturing in India. 9 October | 3:00 PM IST | Online | Free Register: online-sound.zoom.us/webinar… #AdvancedGMP #IndianPharma #PharmaQuality

Ahead of AGMP, a view on AI in manufacturing. Dr. Rajiv Desai, Senior Technical Advisor – Quality and Regulatory, IPA , writes in Express Pharma on what manufacturers need to get right when deploying AI at scale: data, validation, quality, workforce readiness and human judgement. Read the article: expresspharma.in/making-ai-w…… Continue the conversation at the 11th Advanced GMP Workshop, October 8 to 9. Register now: online-sound.zoom.us/webinar… #AdvancedGMP #AIinPharma

9 days to go. US FDA, CDSCO, MHRA and PMDA share one panel on raising global GMP standards, plus AI in quality, data integrity and the history of Indian manufacturing. IPA's 11th Advanced GMP Workshop, 8 to 9 Oct, 3 PM IST. Register now: online-sound.zoom.us/webinar…

World Heart Day is a reminder that progress in cardiovascular care is measured in one place: patient outcomes. Managing heart disease depends on medicines taken consistently, often for life. That makes two things essential. Quality, so that every dose performs as intended. And access, so that treatment remains within reach of the patient. Indian pharmaceutical companies contribute to both, supplying quality-assured affordable medicines to patients in more than 200 countries. IPA remains committed to advancing quality and access, and to strengthening the research and manufacturing capabilities that will bring the next generation of cardiovascular medicines. #WorldHeartDay #IndianPharma #QualityAndAccess

11th Advanced GMP Workshop, Day 1: Thursday 8 Oct, 3 to 8 PM IST. Online, free. DCGI, US FDA India, MHRA and CDSCO with quality leaders from Indian pharma on where GMP quality systems go over the next decade. Register: Webinar Registration - Zoom (online-sound.zoom.us/webinar…) #AdvancedGMP #GMP #IndianPharma